Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 6/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | ACACA | Q13085 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28121713 | 0.89 | GRM2 (0.58) | GRM2ALOX15ALDH1A1LTB4R | |
| SCHEMBL28057819 | 0.89 | GRM2 (0.79) | GRM2ALOX15 | |
| SCHEMBL7222498 | 0.89 | GRM2 (0.59) | GRM2ALOX15ALDH1A1KDM4ELMNA | |
| SCHEMBL31384338 | 0.86 | GRM2 (0.58) | GRM2ALDH1A1KDM4ELMNAACACA | |
| SCHEMBL28879046 | 0.86 | ALDH1A1 (0.71) | GRM2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL3184009 | 0.86 | GRM2 (0.81) | GRM2 | |
| SCHEMBL10987787 | 0.85 | ACACA (0.66) | GRM2ALOX15ALDH1A1KDM4ELMNA | |
| SCHEMBL13187687 | 0.83 | GRM2 (0.59) | GRM2ALDH1A1KDM4ELMNAACACA | |
| SCHEMBL13188224 | 0.82 | GRM2 (0.55) | GRM2ALOX15ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6052793 | 0.82 | MMP2 (0.53) | GRM2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388003-B1 | Colchicine derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3207929-B1 | COLCHICINE DERIVATIVES FOR THE TREATMENT OF CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3207929-A2 | COLCHICINE DERIVATIVES | California Pacific Medical Center (US) | 2017-08-23 | — | — | EP | disclosed |
| CN-106336378-A | Preparation method of quinoline-2-formic ether series | 江西师范大学 | 2017-01-18 | — | — | CN | disclosed |
| EP-1617843-B1 | COLCHICINE DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-1643987-B1 | PODOPHYLLOTOXIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2016-11-30 | — | — | EP | disclosed |
| US-8158809-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2388003-A2 | Colchicine derivatives | California Pacific Medical Center (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | Sutter West Bay Hospitals, dba California Pacific Medical Center and Catholic Healthcare West | 2009-12-03 | — | — | US | disclosed |
| US-7605262-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2009-10-20 | — | — | US | disclosed |
| WO-2005007076-A2 | COLCHICINE DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050004169-A1 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2005-01-06 | — | — | US | disclosed |
| US-6825236-B2 | ACTIVE AGAINST TUMORS IN MICE AND ARE GENERALLY WELL TOLERATED | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | disclosed |
| US-20040204370-A1 | COLCHICINE DERIVATIVES | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-10-14 | — | — | US | disclosed |
| US-5017584-A | Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas | STERLING DRUG INC. (US) | 1991-05-21 | — | — | US | disclosed |
| EP-0126064-A4 | ELECTROACTIVE POLYMERS. | CHEVRON RES (US) | 1985-07-01 | — | — | EP | disclosed |
| US-4519938-A | TRACTABLE, DOPED HETEROCYCLIC RINGS | CHEVRON RESEARCH COMPANY (US) | 1985-05-28 | — | — | US | disclosed |
| US-4499094-A | PREVENTION OF RESPIRATORY, UROGENITAL, CARDIOVASCULAR AND IMMUNOLOGICAL DISORDERS WHEN USING FOR BENZDIAPINES | PHARMUKA LABORATOIRES (FR) | 1985-02-12 | — | — | US | disclosed |
| EP-0126064-A1 | ELECTROACTIVE POLYMERS | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1984-11-28 | — | — | EP | disclosed |
| WO-1984002030-A1 | ELECTROACTIVE POLYMERS | CHEVRON RES (US) | 1984-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004169-A1 | Podophyllotoxin derivatives | APEH, DAGLA, DPY30 | GRM2 4079/4885ALOX15 377/4885ALDH1A1 285/4885 |
| US-20040204370-A1 | COLCHICINE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, NAP1L4 | GRM2 2944/4885ALOX15 4605/4885ALDH1A1 2730/4885 |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | APEH, DAGLA, DPY30 | GRM2 4079/4885ALOX15 377/4885ALDH1A1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.